S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
S&P 500   5,248.07 (+-0.01%)
DOW   39,783.23 (+0.06%)
QQQ   444.85 (+0.00%)
AAPL   171.46 (-1.07%)
MSFT   421.61 (+0.04%)
META   494.55 (+0.14%)
GOOGL   151.06 (+0.13%)
AMZN   179.69 (-0.08%)
TSLA   178.66 (-0.65%)
NVDA   899.25 (-0.36%)
NIO   4.76 (+1.93%)
AMD   179.94 (+0.19%)
BABA   72.12 (+0.74%)
T   17.54 (-0.06%)
F   13.02 (-0.31%)
MU   119.71 (+0.39%)
CGC   9.40 (-1.57%)
GE   179.97 (-0.08%)
DIS   121.22 (+0.20%)
AMC   3.79 (-12.67%)
PFE   27.78 (+0.69%)
PYPL   66.60 (+0.05%)
XOM   115.48 (+0.44%)
NASDAQ:CTSO

Cytosorbents (CTSO) Stock Price, News & Analysis

$0.93
+0.04 (+4.49%)
(As of 03/27/2024 ET)
Today's Range
$0.88
$0.93
50-Day Range
$0.86
$1.04
52-Week Range
$0.84
$4.29
Volume
84,247 shs
Average Volume
101,616 shs
Market Capitalization
$50.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Cytosorbents MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
168.8% Upside
$2.50 Price Target
Short Interest
Healthy
3.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of Cytosorbents in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.21) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.60 out of 5 stars

Medical Sector

705th out of 939 stocks

Surgical & Medical Instruments Industry

75th out of 98 stocks

CTSO stock logo

About Cytosorbents Stock (NASDAQ:CTSO)

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

CTSO Stock Price History

CTSO Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
CTSO Apr 2024 2.500 call
Q4 2023 Cytosorbents Corp Earnings Call
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
Recap: CytoSorbents Q4 Earnings
Cytosorbents earnings preview: what to expect
CTSO Mar 2024 2.500 call
Cytosorbents Corp
CytoSorbents Stock (NASDAQ:CTSO) Insider Trades
CytoSorbents just downgraded at H.C. Wainwright, here's why
What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents
See More Headlines
Receive CTSO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytosorbents and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
3/28/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:CTSO
Employees
198
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$4.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+168.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-28,510,000.00
Pretax Margin
-80.67%

Debt

Sales & Book Value

Annual Sales
$36.35 million
Book Value
$0.52 per share

Miscellaneous

Free Float
49,896,000
Market Cap
$50.48 million
Optionable
Optionable
Beta
0.58
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Phillip P. Chan M.D. (Age 54)
    Ph.D., CEO & Director
    Comp: $541.93k
  • Mr. Vincent J. Capponi M.S. (Age 66)
    President & COO
    Comp: $452.62k
  • Ms. Kathleen P. Bloch CPAMs. Kathleen P. Bloch CPA (Age 69)
    M.B.A., Chief Financial Officer
    Comp: $395.43k
  • Dr. Efthymios N. Deliargyris FACC (Age 56)
    FESC, FSCAI, M.D., Chief Medical Officer
    Comp: $463.15k
  • Ms. Terri Anne Powers M.B.A.
    Vice President of Investor Relations & Corporate Communications
  • Dr. Christian Steiner M.D.
    Executive Vice President of Sales & Marketing
  • Mr. Christopher Cramer M.B.A.
    M.S., Senior Vice President of Business Development
  • Dr. Irina B. Kulinets Ph.D. (Age 69)
    Senior Vice President of Global Regulatory Affairs
  • Jodi Hoover
    Executive
  • Dr. Robert H. Bartlett M.D. (Age 85)
    Co-Chairman of Cardiac Surgery Advisory Board & Consultant
    Comp: $54k

CTSO Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytosorbents stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CTSO shares.
View CTSO analyst ratings
or view top-rated stocks.

What is Cytosorbents' stock price target for 2024?

2 analysts have issued 12 month target prices for Cytosorbents' shares. Their CTSO share price targets range from $1.00 to $4.00. On average, they expect the company's stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 168.8% from the stock's current price.
View analysts price targets for CTSO
or view top-rated stocks among Wall Street analysts.

How have CTSO shares performed in 2024?

Cytosorbents' stock was trading at $1.11 at the start of the year. Since then, CTSO stock has decreased by 16.2% and is now trading at $0.9299.
View the best growth stocks for 2024 here
.

When is Cytosorbents' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our CTSO earnings forecast
.

How were Cytosorbents' earnings last quarter?

Cytosorbents Co. (NASDAQ:CTSO) issued its quarterly earnings results on Thursday, November, 4th. The medical research company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.03. The medical research company had revenue of $9.76 million for the quarter, compared to analyst estimates of $9.96 million. Cytosorbents had a negative net margin of 78.43% and a negative trailing twelve-month return on equity of 120.24%. During the same period in the prior year, the company earned ($0.02) EPS.

What is Phillip Chan's approval rating as Cytosorbents' CEO?

11 employees have rated Cytosorbents Chief Executive Officer Phillip Chan on Glassdoor.com. Phillip Chan has an approval rating of 26% among the company's employees. This puts Phillip Chan in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Cytosorbents to a friend.

What other stocks do shareholders of Cytosorbents own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytosorbents investors own include Rekor Systems (REKR), Advanced Micro Devices (AMD), Micron Technology (MU), Gilead Sciences (GILD), Pfizer (PFE), AbbVie (ABBV), Inovio Pharmaceuticals (INO), OPKO Health (OPK) and Sorrento Therapeutics (SRNE).

Who are Cytosorbents' major shareholders?

Cytosorbents' stock is owned by a variety of institutional and retail investors. Top institutional investors include Granahan Investment Management LLC (8.14%), Skylands Capital LLC (7.32%), Avenir Corp (6.87%), Neuberger Berman Group LLC (4.05%), Neuberger Berman Group LLC (4.05%) and Sargent Investment Group LLC (2.94%). Insiders that own company stock include Al Kraus, Alan D Sobel, Edward Raymond Jones, Jiny Kim, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi.
View institutional ownership trends
.

How do I buy shares of Cytosorbents?

Shares of CTSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CTSO) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners